Advertisement
RGEN vs STXS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGEN is a Buy and STXS is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RGEN’s FA Score shows that 1 FA rating(s) are green whileSTXS’s FA Score has 0 green FA rating(s).
- RGEN’s FA Score: 1 green, 4 red.
- STXS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RGEN’s TA Score shows that 4 TA indicator(s) are bullish while STXS’s TA Score has 5 bullish TA indicator(s).
- RGEN’s TA Score: 4 bullish, 4 bearish.
- STXS’s TA Score: 5 bullish, 4 bearish.
Price Growth
RGEN (@Pharmaceuticals: Other) experienced а -2.20% price change this week, while STXS (@Pharmaceuticals: Other) price change was +0.70% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +4.19%. For the same industry, the average monthly price growth was +5.15%, and the average quarterly price growth was +21.40%.
Reported Earning Dates
RGEN is expected to report earnings on Nov 04, 2025.
STXS is expected to report earnings on Nov 06, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (+4.19% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| RGEN | STXS | RGEN / STXS | |
| Capitalization | 6.87B | 255M | 2,695% |
| EBITDA | 99.5M | -22.41M | -444% |
| Gain YTD | -17.410 | 25.877 | -67% |
| P/E Ratio | 511.11 | N/A | - |
| Revenue | 674M | 31.8M | 2,119% |
| Total Cash | 709M | 6.97M | 10,177% |
| Total Debt | 686M | 5.73M | 11,978% |
RGEN | STXS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 58 | 78 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 91 | 100 | |
PRICE GROWTH RATING 1..100 | 77 | 40 | |
P/E GROWTH RATING 1..100 | 2 | 58 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RGEN's Valuation (95) in the Biotechnology industry is in the same range as STXS (100) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to STXS’s over the last 12 months.
RGEN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as STXS (100) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to STXS’s over the last 12 months.
RGEN's SMR Rating (91) in the Biotechnology industry is in the same range as STXS (100) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to STXS’s over the last 12 months.
STXS's Price Growth Rating (40) in the Medical Specialties industry is somewhat better than the same rating for RGEN (77) in the Biotechnology industry. This means that STXS’s stock grew somewhat faster than RGEN’s over the last 12 months.
RGEN's P/E Growth Rating (2) in the Biotechnology industry is somewhat better than the same rating for STXS (58) in the Medical Specialties industry. This means that RGEN’s stock grew somewhat faster than STXS’s over the last 12 months.
| RGEN | STXS | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 87% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 76% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 79% | 2 days ago 83% |
| Advances ODDS (%) | 16 days ago 75% | 2 days ago 78% |
| Declines ODDS (%) | 2 days ago 81% | 8 days ago 81% |
| BollingerBands ODDS (%) | N/A | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 78% | 2 days ago 76% |
Advertisement
STXS and
Correlation & Price change
A.I.dvisor indicates that over the last year, STXS has been loosely correlated with TWST. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if STXS jumps, then TWST could also see price increases.
| Ticker / NAME | Correlation To STXS | 1D Price Change % | ||
|---|---|---|---|---|
| STXS | 100% | +3.24% | ||
| TWST - STXS | 36% Loosely correlated | -1.91% | ||
| CERS - STXS | 35% Loosely correlated | -1.50% | ||
| SMTI - STXS | 35% Loosely correlated | +0.86% | ||
| RGEN - STXS | 33% Loosely correlated | -1.34% | ||
| VCYT - STXS | 33% Poorly correlated | -1.58% | ||
More | ||||